Cosentyx is a biologic drug that is used to treat a range of autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. While the drug has been found to be effective in treating these conditions, there are concerns about the potential long-term side effects of the drug.

According to Drug Patent Watch [1], there have been no reported cases of long-term harm caused by Cosentyx. However, like all drugs, there are potential side effects associated with the use of Cosentyx. Some of the common side effects of the drug include respiratory infections, diarrhea, and nausea. In rare cases, the drug can cause serious side effects such as liver damage, allergic reactions, and infections.

Medical News Today [2] reports that some studies have suggested that Cosentyx may increase the risk of infections, particularly upper respiratory tract infections. The drug may also increase the risk of developing tuberculosis, so patients should be screened for tuberculosis before starting treatment with Cosentyx.

A study published in Arthritis Research & Therapy [3] found that Cosentyx was generally well-tolerated by patients with psoriatic arthritis over a two-year period. However, the study also found that some patients experienced serious adverse events, including infections and malignancies. The authors of the study noted that further research is needed to determine the long-term safety of the drug.

In conclusion, while there have been no reported cases of long-term harm caused by Cosentyx, there are potential side effects associated with the drug. Patients should be aware of these potential side effects and should discuss any concerns with their healthcare provider. It is important to note that the benefits of Cosentyx in treating autoimmune conditions may outweigh the potential risks for many patients.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.medicalnewstoday.com/articles/drugs-cosentyx-side-effects
[3] https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1882-2